US12485167B2ActiveUtilityA1

Method for inducing cellular immunity to infection by SARS-CoV-2

84
Assignee: UNIV IMAM ABDULRAHMAN BIN FAISALPriority: May 18, 2021Filed: Nov 20, 2023Granted: Dec 2, 2025
Est. expiryMay 18, 2041(~14.8 yrs left)· nominal 20-yr term from priority
Inventors:Iman Almansour
A61K 2039/53A61K 2039/54C12N 2770/20071C12N 2770/20022C12N 2770/20034A61K 2039/545A61K 9/0019A61P 31/14C07K 14/005A61K 2039/57A61K 2039/575A61K 39/12A61K 39/215
84
PatentIndex Score
1
Cited by
27
References
16
Claims

Abstract

A pDNA-based vaccine against SARS-COV-2 and methods for preventing or treating COVID-19 using it.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
         1 . A method for inducing cellular immunity to infection by SARS-COV-2 in a human subject, comprising:
 administering DNA comprising SEQ ID NO: 1, 2, 3 or 4 or a portion thereof that encodes SARS-COV-2 receptor binding domain to the human subject.   
     
     
         2 . The method of  claim 1 , wherein the DNA is administered in at least two intramuscular injections. 
     
     
         3 . The method of  claim 2 , wherein the DNA is administered at intervals of one to three weeks. 
     
     
         4 . The method of  claim 1 , wherein the DNA is incorporated into a plasmid. 
     
     
         5 . The method of  claim 1 , wherein the DNA is S.opt.FL (SEQ ID NO: 2); or S1.opt (SEQ ID NO: 4). 
     
     
         6 . The method of  claim 1 , wherein the DNA comprises SEQ ID NO: 1. 
     
     
         7 . The method of  claim 1 , wherein the DNA comprises the SARS-COV-2 receptor binding domain of SEQ ID NO: 1. 
     
     
         8 . The method of  claim 1 , wherein the DNA lacks all or part of an S2 domain. 
     
     
         9 . The method of  claim 1 , wherein the DNA encodes an S protein consisting of an S1 protein. 
     
     
         10 . The method of  claim 1 , wherein the DNA lacks at least one of a fusion peptide (FP), a heptad repeat region 1 (HR1), a heptad repeat region 2 (HR2), a transmembrane domain (TM) or a cytoplasmic domain. 
     
     
         11 . The method of  claim 1 , wherein the DNA further comprises an enhancer-promoter of mammalian origin. 
     
     
         12 . The method of  claim 1 , wherein the DNA further comprises a cytomegalovirus (CMV) enhancer-promoter of mammalian origin. 
     
     
         13 . The method of  claim 1 , wherein the DNA comprises a pcDNA3.1(+) vector. 
     
     
         14 . The method of  claim 1 , wherein the DNA is S.opt.FL (SEQ ID NO: 2). 
     
     
         15 . The method of  claim 1 , wherein the DNA is S1.opt (SEQ ID NO: 4). 
     
     
         16 . The method of  claim 2 , wherein the DNA is administered as three or more intramuscular injections at intervals of one to three weeks.

Join the waitlist — get patent alerts

Track US12485167B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.